| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Q2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 32% over Q2 2025 |
| 29 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 28, 2026, Castle Biosciences, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following matters and cast their votes as set f... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Q1 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q1 2025 |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 |
| 08 Aug 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the corporati... |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 |
| 23 May 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
ONE: He is the duly elected and acting President and Chief Executive Officer of Castle Biosciences, Inc., a Delaware corporation. |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 |
| 04 Nov 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million |
| 05 Aug 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million |
| 24 May 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On May 23, 2024, Castle Biosciences, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following matters and cast their votes as set f... |
| 02 May 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million |
| 27 Mar 2024 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARIL... |
| 28 Feb 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance |
| 08 Jan 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the... |
Loading...